Streetbeat News

SCPH

scPharmaceuticals Inc.

https://www.scpharmaceuticals.com

Industry

Biotechnology

scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion in patients with heart failure. Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-negative organisms. The company has a development agreement with West Pharmaceutical Services, Inc. for development of single use SmartDose device. scPharmaceuticals Inc. was incorporated in 2013 and is headquartered in Burlington, Massachusetts.

Open

4.33

Mkt cap

210M

Volume

174K

High

4.40

P/E Ratio

-2.70

52-wk high

6.71

Low

4.18

Div yield

N/A

52-wk low

3.24

HC Wainwright & Co. analyst Douglas Tsao has reiterated a Buy rating on scPharmaceuticals (NASDAQ:SCPH) and maintained a price target of $18.

Portfolio Pulse from Benzinga Newsdesk

May 15, 2024 | 10:57 am

scPharmaceuticals (NASDAQ:SCPH) reported Q1 2024 earnings with a GAAP EPS of $(0.36), surpassing the $(0.44) estimate, and sales of $6.10M, exceeding the $5.98M estimate. This represents a 195.69% increase in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 8:06 pm

scPharmaceuticals has started enrolling participants for a pivotal pharmacokinetic study of its FUROSCIX Auto-Injector, aimed at complementing the existing FUROSCIX On-body Infusor. The company expects to release topline data by Q3 2024 and plans to submit a Supplemental New Drug Application (sNDA) by the end of 2024, contingent on positive results.

Portfolio Pulse from Benzinga Newsdesk

April 24, 2024 | 12:01 pm

In Friday's pre-market session, health care stocks showed significant movement. Protara Therapeutics led the gainers with a 40.3% increase, while Aesthetic Medical Intl experienced the largest drop among the losers, declining by 17.8%. Other notable movers include Candel Therapeutics and Etao International with substantial gains, and TC BioPharm and Imunon among the losers.

Portfolio Pulse from Benzinga Insights

April 05, 2024 | 12:09 pm

HC Wainwright & Co. analyst Douglas Tsao has reiterated a Buy rating on scPharmaceuticals (NASDAQ:SCPH), maintaining an $18 price target on the stock.

Portfolio Pulse from Benzinga Newsdesk

March 14, 2024 | 11:23 am

scPharmaceuticals (NASDAQ:SCPH) reported Q4 earnings with an EPS of $-0.35, beating estimates by 17.0% and showing a revenue increase of $6.10 million from the previous year. However, the company had missed EPS estimates in the last quarter, leading to a 9.0% share price drop the following day.

Portfolio Pulse from Benzinga Insights

March 13, 2024 | 8:10 pm

scPharmaceuticals (NASDAQ:SCPH) reported Q4 2023 earnings with a GAAP EPS of $(0.35), surpassing the $(0.42) estimate, and sales of $6.096M, exceeding the $5.525M estimate. This represents a 16.67% decrease in losses per share compared to the same period last year, and a 10.33% increase in sales.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 8:07 pm

Numerous companies are scheduled to report their earnings on March 13, 2024, covering a wide range of industries from biotech to retail. Notable mentions include Dollar Tree with expected earnings of $2.65 per share on $8.67 billion revenue, and Lennar with an estimate of $2.20 per share on $7.39 billion revenue. Several companies are anticipated to report losses, such as ZIM Integrated Shipping with a projected loss of $1.29 per share.

Portfolio Pulse from Benzinga Insights

March 13, 2024 | 10:15 am

scPharmaceuticals (NASDAQ:SCPH) is scheduled to release its quarterly earnings report on March 13, 2024, with an expected EPS of $-0.42. The company's past earnings performance shows a mixed impact on its stock price, with the last quarter's miss resulting in an 8.74% drop. Shares are currently trading at $5.28, down 24.53% over the last year. Investors are looking for positive guidance for the next quarter.

Portfolio Pulse from Benzinga Insights

March 12, 2024 | 3:02 pm

In Monday's pre-market session, several healthcare stocks experienced significant movements. MSP Recovery (LIFW) led the gainers with a 23.1% rise, while Aethlon Medical (AEMD) saw the largest decline among the losers, dropping 20.9%. Other notable movers included 60 Degrees (SXTP), Telesis Bio (TBIO), scPharmaceuticals (SCPH), and OpGen (OPGN) with substantial gains, and XBiotech (XBIT), NexImmune (NEXI), Bionomics (BNOX), Senti Biosciences (SNTI), and Celularity (CELU) with notable losses.

Portfolio Pulse from Benzinga Insights

January 22, 2024 | 1:06 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.